JPWO2022200786A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022200786A5 JPWO2022200786A5 JP2023558499A JP2023558499A JPWO2022200786A5 JP WO2022200786 A5 JPWO2022200786 A5 JP WO2022200786A5 JP 2023558499 A JP2023558499 A JP 2023558499A JP 2023558499 A JP2023558499 A JP 2023558499A JP WO2022200786 A5 JPWO2022200786 A5 JP WO2022200786A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- compound
- isobutyl
- formula
- thienyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims 3
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 206010062106 Respiratory tract infection viral Diseases 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- ZSINGWRYEZQBHI-UHFFFAOYSA-N CC(C)CC(S1)=CC(C(C=CC(CN2C(C)=NC=C2)=C2)=C2F)=C1S(NC(NCCO)=O)(=O)=O Chemical compound CC(C)CC(S1)=CC(C(C=CC(CN2C(C)=NC=C2)=C2)=C2F)=C1S(NC(NCCO)=O)(=O)=O ZSINGWRYEZQBHI-UHFFFAOYSA-N 0.000 claims 1
- PNYYUFYWWURGMZ-UHFFFAOYSA-N CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C(C)(C)C)=NC=C3)C=C2)=C1S(NC(NCC(C)(C)O)=O)(=O)=O Chemical compound CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C(C)(C)C)=NC=C3)C=C2)=C1S(NC(NCC(C)(C)O)=O)(=O)=O PNYYUFYWWURGMZ-UHFFFAOYSA-N 0.000 claims 1
- LPKCDDPDNZABRC-UHFFFAOYSA-N CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C(C)(C)C)=NC=C3)C=C2)=C1S(NC(NCCO)=O)(=O)=O Chemical compound CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C(C)(C)C)=NC=C3)C=C2)=C1S(NC(NCCO)=O)(=O)=O LPKCDDPDNZABRC-UHFFFAOYSA-N 0.000 claims 1
- YEDKJHPEFFLLRU-UHFFFAOYSA-N CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C(C)C)=NC=C3)C=C2)=C1S(NC(NCCO)=O)(=O)=O Chemical compound CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C(C)C)=NC=C3)C=C2)=C1S(NC(NCCO)=O)(=O)=O YEDKJHPEFFLLRU-UHFFFAOYSA-N 0.000 claims 1
- SWHIGVPQEYFRRE-UHFFFAOYSA-N CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C)=NC=C3)C(F)=C2)=C1S(NC(NCCO)=O)(=O)=O Chemical compound CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C)=NC=C3)C(F)=C2)=C1S(NC(NCCO)=O)(=O)=O SWHIGVPQEYFRRE-UHFFFAOYSA-N 0.000 claims 1
- CGFVTBXTYJNHDX-UHFFFAOYSA-N CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C)=NC=C3)C=C2)=C1S(NC(NCC(C)(C)O)=O)(=O)=O Chemical compound CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C)=NC=C3)C=C2)=C1S(NC(NCC(C)(C)O)=O)(=O)=O CGFVTBXTYJNHDX-UHFFFAOYSA-N 0.000 claims 1
- UYSPEKQFTWZONB-UHFFFAOYSA-N CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C)=NC=C3)C=C2)=C1S(NC(NCCCO)=O)(=O)=O Chemical compound CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C)=NC=C3)C=C2)=C1S(NC(NCCCO)=O)(=O)=O UYSPEKQFTWZONB-UHFFFAOYSA-N 0.000 claims 1
- PRTLZMJRDMVGPM-UHFFFAOYSA-N CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C)=NC=C3)C=C2)=C1S(NC(NCCO)=O)(=O)=O Chemical compound CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C)=NC=C3)C=C2)=C1S(NC(NCCO)=O)(=O)=O PRTLZMJRDMVGPM-UHFFFAOYSA-N 0.000 claims 1
- MMLKEWURCNBJDX-UHFFFAOYSA-N CCC1=NC=CN1CC(C=CC(C(C=C(CC(C)C)S1)=C1S(NC(NCC1(CCCCC1)O)=O)(=O)=O)=C1)=C1F Chemical compound CCC1=NC=CN1CC(C=CC(C(C=C(CC(C)C)S1)=C1S(NC(NCC1(CCCCC1)O)=O)(=O)=O)=C1)=C1F MMLKEWURCNBJDX-UHFFFAOYSA-N 0.000 claims 1
- PLOBSLBDFLPTAO-UHFFFAOYSA-N CCC1=NC=CN1CC(C=CC(C(C=C(CC(C)C)S1)=C1S(NC(NCCO)=O)(=O)=O)=C1)=C1F Chemical compound CCC1=NC=CN1CC(C=CC(C(C=C(CC(C)C)S1)=C1S(NC(NCCO)=O)(=O)=O)=C1)=C1F PLOBSLBDFLPTAO-UHFFFAOYSA-N 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- -1 methylcyclohexyl Chemical group 0.000 claims 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2104038.1 | 2021-03-23 | ||
| GBGB2104038.1A GB202104038D0 (en) | 2021-03-23 | 2021-03-23 | New compounds |
| PCT/GB2022/050726 WO2022200786A1 (en) | 2021-03-23 | 2022-03-23 | Selective angiotensin ii receptor ligands |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024511452A JP2024511452A (ja) | 2024-03-13 |
| JP2024511452A5 JP2024511452A5 (https=) | 2025-03-31 |
| JPWO2022200786A5 true JPWO2022200786A5 (https=) | 2025-03-31 |
Family
ID=75689746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023558499A Pending JP2024511452A (ja) | 2021-03-23 | 2022-03-23 | 選択的アンジオテンシンｉｉ受容体リガンド |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240174657A1 (https=) |
| EP (1) | EP4313976A1 (https=) |
| JP (1) | JP2024511452A (https=) |
| CN (1) | CN117203204A (https=) |
| CA (1) | CA3212780A1 (https=) |
| GB (1) | GB202104038D0 (https=) |
| WO (1) | WO2022200786A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202104033D0 (en) * | 2021-03-23 | 2021-05-05 | Vicore Pharma Ab | New compounds |
| IE20230600A3 (en) | 2022-12-22 | 2025-09-24 | Vicore Pharma Ab | A method of treating a patient diagnosed with an interstitial lung disease |
| WO2024149712A1 (en) * | 2023-01-09 | 2024-07-18 | Vicore Pharma Ab | Selective angiotensin ii compounds |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5312820A (en) | 1992-07-17 | 1994-05-17 | Merck & Co., Inc. | Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines |
| US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| SE9800550D0 (sv) | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| CA2449150C (en) | 2001-05-31 | 2011-07-12 | Vicore Pharma Ab | Tricyclic compounds useful as angiotensin ii agonists |
| KR100938817B1 (ko) * | 2001-05-31 | 2010-01-26 | 바이코어 파마 아베 | 안지오텐신 ⅱ 작용제로 유용한 삼중고리 화합물 |
| WO2003064414A1 (en) * | 2002-01-29 | 2003-08-07 | Vicore Pharma Ab. | Tricyclic compounds useful as angiotensin ii agonists |
| WO2004046141A1 (en) | 2002-11-21 | 2004-06-03 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| US8835471B2 (en) | 2010-06-11 | 2014-09-16 | Vicore Pharma Ab | Use of angiotensin II agonists |
| BR112017012337A2 (pt) | 2014-12-12 | 2018-02-27 | Vicore Pharma Ab | Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação. |
| WO2016107879A2 (en) | 2014-12-30 | 2016-07-07 | Vicore Pharma Ab | New use of angiotensin ii receptor agonists |
| CN107405406A (zh) | 2015-03-02 | 2017-11-28 | 维科尔药物公司 | 用于治疗肺纤维化的血管紧张素ii受体激动剂 |
| WO2017221012A1 (en) | 2016-06-21 | 2017-12-28 | Vicore Pharma Ab | Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity |
| GB201710906D0 (en) | 2017-07-06 | 2017-08-23 | Vicore Pharma Ab | Compounds and methods for treating peripheral neuropathy |
| GB201913603D0 (en) * | 2019-09-20 | 2019-11-06 | Vicore Pharma Ab | New compounds |
| GB202013721D0 (en) * | 2020-09-01 | 2020-10-14 | Vicore Pharma Ab | New compounds |
-
2021
- 2021-03-23 GB GBGB2104038.1A patent/GB202104038D0/en not_active Ceased
-
2022
- 2022-03-23 EP EP22714510.9A patent/EP4313976A1/en active Pending
- 2022-03-23 WO PCT/GB2022/050726 patent/WO2022200786A1/en not_active Ceased
- 2022-03-23 CN CN202280030667.9A patent/CN117203204A/zh active Pending
- 2022-03-23 CA CA3212780A patent/CA3212780A1/en active Pending
- 2022-03-23 JP JP2023558499A patent/JP2024511452A/ja active Pending
- 2022-03-23 US US18/283,487 patent/US20240174657A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9511073B2 (en) | Aromatic amides and uses thereof | |
| JP2021514001A5 (https=) | ||
| JP2021535177A5 (https=) | ||
| JP2021511360A5 (https=) | ||
| JP2021535174A5 (https=) | ||
| JP2013526494A5 (https=) | ||
| JP2008508214A (ja) | 女性の性障害の治療用ピペラジン誘導体 | |
| JP2020532550A5 (https=) | ||
| JP2007526257A5 (https=) | ||
| JP2004532276A5 (https=) | ||
| JP2017538697A5 (https=) | ||
| ES2586145T3 (es) | Derivados de 5-(bifenil-4-il)-3-fenil-1,2,4-oxadiazolilo como ligandos en los receptores de esfingosina 1-fosfato (S1P) | |
| JPWO2021053344A5 (https=) | ||
| JPWO2022200786A5 (https=) | ||
| JP2010540569A5 (https=) | ||
| JPWO2020216766A5 (https=) | ||
| JPWO2020051105A5 (https=) | ||
| US20130079318A1 (en) | Beta-lactamase inhibitory compounds | |
| JPWO2021186185A5 (https=) | ||
| JPWO2020051139A5 (https=) | ||
| JPWO2022049372A5 (https=) | ||
| JPWO2022200787A5 (https=) | ||
| JPWO2022200785A5 (https=) | ||
| JPWO2020181034A5 (https=) | ||
| JPWO2023281271A5 (https=) |